StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Johnson & Johnson (JNJ) Janssen Gains FDA Approval for Plaque Psoriasis Treatment TREMFYA
July 13, 2017 4:12 PM
Johnson & Johnson's (NYSE: JNJ) Janssen Biotech, Inc.(Janssen) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Next Articles
Johnson & Johnson (JNJ) Declares $0.84 Quarterly Dividend; 2.5% Yield
July 17, 2017 10:34 AM
Janssen Announces U.S. FDA Approval Of TREMFYAâ„¢ (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis
July 13, 2017 4:11 PM